Breaking News, Collaborations & Alliances

Memory Pharma Earns Bipolar Milestone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Memory Pharmaceuticals Corp. earned a milestone payment of $960,000 from the Stanley Medical Research Institute (SMRI) based on progress of an ongoing Phase IIa trial of MEM 1003 in patients with acute mania in bipolar disorder. “We are pleased to have earned our first milestone payment from SMRI, and we are particularly pleased by enrollment in this trial to date,” said Stephen R. Murray, M.D., Ph.D., vice president of clinical development. “We have increased the number ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters